Dextroamphetamine for cocaine-dependence treatment: A double-blind randomized clinical trial

John Grabowski, Howard Rhoades, Joy Schmitz, Angela Stotts, Lee Ann Daruzska, Dan Creson, F. Gerard Moeller

Research output: Contribution to journalArticlepeer-review

225 Scopus citations


A properly implemented agonist treatment regimen should improve retention and reduce illicit drug use. Cocaine-dependent subjects (N = 128) were enrolled in a 12-week randomized, double-blind, placebo-controlled trial. In the multistage dosing design, subjects initially received placebo (PBO) or 15 to 30 mg of dextroamphetamine sulfate, sustained-release capsules. At week 5, the dose doubled to 30 mg or 60 mg for active groups. Subjects attended the clinic twice a week, provided urine samples, obtained medication, and had one behavioral therapy session a week. Retention was best for the 15- to 30-mg group, whereas the proportion of benzoylecgonine-positive urine screens was, from lowest to highest, 30 to 60 mg, 15 to 30 mg, and PBO at study end. Dosing must be refined. The results provide support for additional examination of the agonist model in psychostimulant-dependence treatment.

Original languageEnglish (US)
Pages (from-to)522-526
Number of pages5
JournalJournal of Clinical Psychopharmacology
Issue number5
StatePublished - 2001


Dive into the research topics of 'Dextroamphetamine for cocaine-dependence treatment: A double-blind randomized clinical trial'. Together they form a unique fingerprint.

Cite this